Motley Fool: Check out Caraco; SciClone names new CFO;

> If you're looking to invest in a pharma company, the Motley Fool thinks you would be wise to check out Caraco Pharma. Report

> US District Court Judge Gregory Frost denied a bid to force the FDA to respond to a Freedom of Information Act request for documents regarding Provenge, a vaccine for prostate cancer that FDA has held up pending further research. Report

> The biotechnology company SciClone Pharmaceuticals has named Gary Titus--formerly of Kosan Biosciences--its new chief financial officer, effective December 8, 2008. Report

> Denmark's Zealand Pharma has licensed out the worldwide rights--outside of the Nordic countries--to an early-stage compound targeting chemotherapy-induced diarrhea. Helsinn gained marketing rights to the drug as part of a package worth up to $177 million. Report

> Biotech giant Biogen Idec is joining the migration of Cambridge drug developers to the burbs. The company has inked a lease for 350,000 square feet of space for its new corporate headquarters in Weston, according to the Boston Globe. Report

> Last May, Enzon said the timing was right to spin off its biotech business into a new company. Yesterday, it said that the financial turmoil roiling world markets had made that spinoff plan a non-starter. Report

> Quintiles Transnational, one of the world's largest CROs has inked a deal to buy Targeted Molecular Diagnostics of Westmont, IL. The TMD deal will give Quintiles a bigger presence in the clinical research field for oncology drugs, a hot area in drug testing these days. Report

> A number of companies announced layoffs and/or cutbacks this week, including Pressure BioSciences, Titan Pharmaceuticals, Targeted Genetics, InSite Vision and WuXi PharmaTech Cayman. Report

> Researchers at the Wistar Institute have found a number of receptors on the surface of T cells that can be targeted by new drugs to keep the body's immune system in top condition. Report

> Last week the Juvenile Diabetes Research Foundation found their new chief at a stem cell company. Novocell CEO Alan Lewis was tapped to head the group, which funds cutting edge research projects into new therapies to fight Type 1 diabetes. Report

> Canada's Enobia Pharma has been testing a new drug designed to fight hypophosphatasia, a rare genetic disease that causes bone disorders in adults and rickets in children. Report

And Finally... Now that pharma won't be allowed to fill physician pockets with fun money for food and other expenditures at conventions, some cities are wary of holding events, citing concerns about gifting laws potentially being broken. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.